Meet the jury: Gut Microbiota in IBD: From description to therapeutic modulation by prof. dr. Harry Sokol

You are kindly invited  to the ‘Meet the Jury lecture’ by prof. dr. Harry Sokol (Sorbonne University, Paris) on Gut Microbiota in IBD: From description to therapeutic modulation.
Please find the invitation here.

Date: December 6th
Time: 14h – 15h
Location: Auditorium UZ (Leuven), UZ6 02.08 (UZ Gasthuisberg: Groene straat, poort 6, niveau 2)
Teams link

Abstract 
The study of gut microbiota in Inflammatory Bowel Disease (IBD) represents a crucial exploration from mere description to therapeutic modulation. In this context, the presentation delves into the intricate relationship between the gut microbiota and IBD, elucidating shifts in microbial composition and function that play a pivotal role in the disease’s pathogenesis. The focus extends beyond understanding the microbial alterations associated with IBD, aiming to bridge the gap between observation and practical intervention. This presentation critically examines emerging therapeutic strategies, such as probiotics, prebiotics, antibiotics, and fecal microbiota transplantation, providing insights into their efficacy in modulating the dysbiotic microbiome and alleviating IBD symptoms. Furthermore, it explores the influence of diet and lifestyle on the gut microbiota, offering a holistic perspective on patient-centered approaches for managing IBD. The ultimate goal is to pave the way for a nuanced understanding of the interplay between gut microbiota and IBD, driving toward personalized and effective interventions for individuals grappling with these challenging disorders.

About the speaker
Harry Sokol is a Professor in the Gastroenterology department at Saint Antoine Hospital in Paris, France. He serves as the co-director of the Microbiota, Gut & Inflammation team at Sorbonne Université and is a group leader in the Micalis institute (INRA). Renowned internationally, Sokol has authored over 190 papers in major journals, focusing on Inflammatory Bowel Disease (IBD) and gut microbiota. His groundbreaking research highlights IBD-associated dysbiosis and the significant role of Faecalibacterium prausnitzii in gut homeostasis and IBD. Currently, Sokol’s work delves into understanding gut microbiota-host interactions in health and diseases, particularly IBD, aiming to develop innovative treatments. Beyond basic science, he is actively involved in translational research and leads initiatives related to Fecal Microbiota Transplantation in Crohn’s disease and ulcerative colitis. As the president of the French group of Fecal Microbiota Transplantation, Sokol oversees nationwide randomized control trials evaluating this approach.

Contact info: Sara<dot>Deleu<at>kuleuven<dot>be